Brief: Zhejiang Huahai Pharmaceutical's Unit Signs Global Research And Licensing Deal With Almirall,S.A.
27/03/2026 08:16
March 27 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd 600521.SS: SAYS UNIT SIGNED GLOBAL RESEARCH AND LICENSING DEAL WITH ALMIRALL,S.A. WORTH UP TO $340 MILLION Source text Further company coverage: 600521.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24